Figure 4.

GPC3/CD47 biAb exhibits excellent antitumor activity in a hHCC xenograft model

(A−C) Hep3B-Luc23 cells were subcutaneously inoculated into NOD-SCID mice. Mice were divided into four groups (n = 5/group) with similar mean tumor bioluminescence intensities, followed by treatment with PBS (Ctrl) or the indicated antibodies (10 mg/kg) two times per week for 3 weeks. Tumor growth was measured by bioluminescence (A and B) and by caliper (C). (D−F) Tumor-bearing mice were prepared and divided into three groups (n = 5/group) as described in (A). These mice were treated with PBS, GPC3/CD47 biAb (10 mg/kg), or a combination of anti-GPC3 mAb and anti-CD47 mAb (5 mg/kg for each). Tumor growth was measured by bioluminescence (D and E) and by caliper (F). All tumor volumes are shown as the mean ± SEM (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001; 2-way ANOVA followed by Tukey’s multiple comparisons test). See also Figure S4.